Merck (MRK) Income towards Parent Company (2009 - 2026)
Merck (MRK) posted quarterly Income towards Parent Company of -$4.2 billion for Q1 2026, down 182.77% year-over-year from $5.1 billion in Q1 2025, and down 242.1% quarter-over-quarter from $3.0 billion in Q4 2025.
Merck (MRK) Income towards Parent Company (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Income towards Parent Company for 17 consecutive years, with -$4.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 182.77% year-over-year to -$4.2 billion; the TTM figure through Mar 2026 stood at $9.0 billion (down 48.61% YoY), while the FY2025 annual figure was $18.3 billion, up 6.6% from the prior year.
- Income towards Parent Company fell to -$4.2 billion in Q1 2026 per MRK's latest filing, from $3.0 billion in the prior quarter.
- Across five years, Income towards Parent Company topped out at $5.8 billion in Q3 2025 and bottomed at -$6.0 billion in Q2 2023.
- Historically, Income towards Parent Company has averaged $2.4 billion across 4 years, with a median of $3.7 billion in 2024.
- Annual changes were most pronounced in 2024 — Income towards Parent Company soared 405.38% — and 2026, when it slumped 182.77%.
- Merck's Income towards Parent Company stood at -$1.2 billion in 2023, then jumped by 405.38% to $3.7 billion in 2024, then slipped by 20.89% to $3.0 billion in 2025, then sank by 242.1% to -$4.2 billion in 2026.
- Business Quant data shows MRK's Income towards Parent Company at -$4.2 billion in Q1 2026, $3.0 billion in Q4 2025, and $5.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.34 Bn |
| Mar 31, 2026 | -4.21 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.09 Bn |
| Dec 31, 2024 | 3.74 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.77 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.97 Bn |
| Mar 31, 2023 | 2.83 Bn |
| Dec 31, 2021 | -59.00 Mn |
| Jun 30, 2021 | 332.00 Mn |
| Mar 31, 2021 | 434.00 Mn |
| Dec 31, 2020 | 523.00 Mn |
| Sep 30, 2020 | 619.00 Mn |
| Jun 30, 2020 | 665.00 Mn |